Eli Lilly: to lower diabetes treatment prices
(CercleFinance.com) - Eli Lilly plans to introduce a lower-priced version of its Humalog insulin, with costs 50% lower than the current list prices of the diabetes treatment.
In a statement, the US drugmaker said it wants to help fix the problem of high costs for Americans living with chronic conditions.
"We hope our announcement is a catalyst for positive change across the U.S. health care system," Lilly CEO David Ricks said.
The lower-priced version of Humalog - which will be called Insulin Lispro - will be available in vial and pen options.
The list price of a single vial will be 137.35 dollars, while the list price of a five-pack of pens will be 265.20 dollars.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
In a statement, the US drugmaker said it wants to help fix the problem of high costs for Americans living with chronic conditions.
"We hope our announcement is a catalyst for positive change across the U.S. health care system," Lilly CEO David Ricks said.
The lower-priced version of Humalog - which will be called Insulin Lispro - will be available in vial and pen options.
The list price of a single vial will be 137.35 dollars, while the list price of a five-pack of pens will be 265.20 dollars.
Copyright (c) 2019 CercleFinance.com. All rights reserved.